Photo by Erin O’Flynn/The Daily Beast/Getty Images
com New variants and sub-variants of COVID Develop faster and faster, each of which destroys the power of the flagship. vaccineThe search continues for a new type of vaccine that works well against current and future forms of the novel coronavirus.
Now researchers at the National Institutes of Health in Maryland believe they have created a new approach to vaccine development that could lead to a longer-acting dose. As a bonus, it can also work on another coronavirusand not just the SARS-CoV-2 virus that causes COVID.
The National Institutes of Health team reported their findings in Peer reviewed study what appeared in the magazine host cell and microbe earlier this month.
The key to a potential NIH vaccine project is a part of the virus called the “spinal cochlea”. It’s a helical structure within a spike protein, which is part of the virus that helps it attach to our cells and infect them.
Many current vaccines target the spike protein. But none of them specifically target spiny snails. However, there are good reasons to focus on this particular part of the pathogen. While many regions of the spike protein tend to change a lot as the virus mutates, the same thing happens with the snail’s spine. No.
This gives scientists “hope that an antibody that targets this region will be more durable and broadly effective,” Joshua Tan, lead scientist at the NIH group, told The Daily Beast.
Vaccines that target and “bind” to, for example, the region of the receptor-binding domain of the spike protein may lose their effectiveness if the virus grows in that region. The great thing about spiny snails from an immunological standpoint is that they don’t mutate. At least he didn’t mutate For nowThree years of the COVID pandemic.
Therefore, a vaccine that binds to the SARS-CoV-2 snail should work for a long time. And it should also work on all other coronaviruses, which also include spinal snails – and there are dozens of them, including several such as SARS-CoV-1 and MERS, which have already increased the number of animals and caused outbreaks in humans.
To test their hypothesis, NIH researchers extracted antibodies from 19 recovered COVID patients and tested them on samples from five different coronaviruses, including SARS-CoV-2, SARS-CoV-1 and MERS. Of the 55 different antibodies, most are concentrated on parts of the virus that are prone to strong mutations. 11 targets only the snail’s spine.
But the 11 people who chose the spinal IUD did better on average with four coronaviruses. (A fifth virus, HCoV-NL63, excludes all antibodies.) The NIH team isolated the best coiled spike antibody, COV89-22, and also tested it in hamsters infected with newer Omicron sub-variants of the COVID variant. The team found that “hamsters treated with COVID-89-22 had a lower rate of disease.”
The results are promising. These results define a class of … broadly neutralizing antibodies. [coronaviruses] Aimed at the trunk of a snail,” the researchers wrote.
The champagne hasn’t erupted yet. The NIH panel cautioned that “while these data are useful for vaccine development, we did not test the vaccines in this study and therefore cannot draw definitive conclusions about the effectiveness of coiled vaccines.”
It’s one thing to test for certain antibodies in a hamster. It is another matter to develop and test and get approval for an entirely new class of vaccines. “It’s very difficult, and most things start with good ideas failing for one reason or another,” James Lawler, an infectious disease specialist at the University of Nebraska Medical Center, told The Daily Beast.
Although it turns out that antibodies against the backbone of the cochlea wide effective, it is not clear how they compare to more specific antibodies. In other words, an acne spiral injection may work against a group of different but related viruses, but it is less effective against any one virus than an injection designed specifically for that virus. “More trials are needed to evaluate whether they provide adequate protection in humans,” Tan said of cochlear and spinal antibodies.
There is a lot of work to be done before the spiral vaccine is available at Zawia Pharmacy. There are many things that can interfere with this work. Additional research may conflict with the NIH team’s findings. The new vaccine design may not work as well in humans as it does in hamsters.
A new vaccine may also be unsafe, not feasible to produce, or too expensive to be widely distributed. Barton Haynes, an immunologist at Duke University, told The Daily Beast that last year he reviewed snail-backbone vaccine projects and concluded they would be too expensive to justify the large investment. The main problem, he says, is that spiny snail antibodies are less effective and “difficult to induce” than the mother’s B cells.
The harder the pharmaceutical industry has to work to produce a vaccine, and the more vaccine has to be packaged in a single dose to make up for the lower potency, the less economical a mass-produced vaccine will be.
Perhaps the spiral acne scam is in our future. Or maybe not. In any case, it is encouraging that scientists are gradually moving in this direction. Global Corona Virus Vaccine🇧🇷 One that could work for many years on a wide range of related viruses.
COVID, for example, is not going anywhere. And with each mutation, it risks becoming unrecognizable in modern vaccines. We need a mutagenic vaccine.
